DHRS12

Across TCGA pan-cancer cohorts, DHRS12 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DHRS12 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DHRS12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRS12 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where DHRS12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.268	1.000	.001	62	view →
PDAC	OS	Median	All	0.455	0.645	.005	20	view →
LUAD	DFS	Tertile	III,IV	0.991	0.286	.024	11	view →
GBM	OS	Tertile	All	0.436	0.913	.022	10	view →
HNSC	OS	Quartile	All	1.000	0.844	.013	7	view →
UCEC	DFS	Tertile	All	0.724	1.000	.026	4	view →
LSCC	DFS	Quartile	All	1.000	0.418	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DHRS12–CCRCC (DFS)

Open the CCRCC breakdown →